in the first year, there is a significant risk of death based on initial presentation, as well as underlying comorbidities. To improve long-term survival, aggressive medical management and medical surveillance is warranted.
IP097. EVAR With Contemporary Volume-Dependent Sac Embolization Compared to Endovascular Aneurysm Sealing System (EVAS) in the Prevention of Type II Endoleak and Its Complications
Objectives: The goal of this study was to compare outcomes of endovascular aneurysm repair (EVAR) with contemporary volume-dependent sac embolization with fibrin glue and coils (Embo-EVAR), vs endovascular aneurysm sealing system (EVAS) with the Nellix device (Endologix Inc, Irvine, Calif) in the prevention of type II endoleaks (ELII) and their complications.
Methods: This retrospective study included patients with abdominal aortic aneurysm elected for EVAR and identified as "at risk" for ELII in two vascular centers between 2014 and 2016. The definition "at risk" for ELII was patency of inferior mesenteric artery (IMA) with >3 mm diameter; patency of at least three pairs of lumbar arteries, or two pairs of lumbar arteries plus sacral artery or accessory renal artery or any diameter patent IMA. EVAS was performed according to device instructions for use. Overall, 130 patients underwent endovascular repair (Embo-EVAR, n ¼ 75 [57.7%]; EVAS, n ¼ 55 [42.3%]). ELII rates during follow-up were compared. Freedom from any reintervention and freedom from ELII-related reintervention were compared using Kaplan-Meier estimates.
Results: Patient characteristics and Society for Vascular Surgery comorbidity scores (0.93 6 0.53 vs 0.93 6 0.52; P ¼ 1.00) as also mean aneurysm sac diameter (61 6 13 vs 57 6 8 mm; P ¼ .05) and mean sac patent lumen diameter (43 6 10 vs 45 6 9 mm; P ¼ .24) were similar between Embo-EVAR and EVAS. However, Embo-EVAR had a significantly higher number of cases with aneurysm sac patent lumen diameter >60 mm compared to EVAS (8% vs 0%; P ¼ .03). Operative time (151 6 37 vs 115 6 23 minutes; P < .001) and length of hospitalization (4.0 6 4.6 vs 2.9 6 1.8 days; P ¼ .02) were longer in Embo-EVAR compared to EVAS. Freedom from ELII was lower in Embo-EVAR at 3 months (92% vs 100%; P ¼ .04), but was similar between Embo-EVAR and EVAS at 6 (93% vs 98%; P ¼ .40), 12 (90% vs 98%; P ¼ .27), and 24 months (100% vs 100%; P ¼ 1.00). At 24 months freedom from any reintervention (Embo-EVAR, 98% vs EVAS; 95%; P ¼ .19) and freedom from ELII-related reintervention were similar (100% for both groups; P ¼ 1.00). Within Embo-EVAR, ELII-related reintervention was 0% both for patients with <60 mm and >60 mm sac patent lumen (P ¼ .1).
Conclusions: EVAS compared to Embo-EVAR is associated to shorter operative time and length of hospitalization. Although further confirmatory studies are needed, both Embo-EVAR and EVAS seem to be associated to a low rate of ELII and EIIerelated reintervention over the midterm follow-up. Embo-EVAR may be a valid alternative for prevention of EII-complications, also for large aneurysm with a sac patent lumen diameter > 60 mm.
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